RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug combo aims to outsmart returning myeloma
Disease control Not yet recruitingThis study tests a new combination of two drugs (teclistamab and pomalidomide) against the usual three-drug treatment for multiple myeloma that has come back after initial therapy. About 162 adults with relapsed or refractory myeloma will take part. The goal is to see if the new …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Targeted radiation and stem cell transplant offer new hope for tough myeloma
Disease control Not yet recruitingThis early-stage trial tests a new approach for people with high-risk multiple myeloma, including those whose cancer has returned or not responded to treatment. Participants receive a radioactive antibody that seeks out and kills myeloma cells, followed by chemotherapy, radiation…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC
-
New Two-Drug combo tested in battle against stubborn blood cancer
Disease control Not yet recruitingThis study aims to see if a new two-drug combination (daratumumab + teclistamab) works better than current standard drug combinations for people with multiple myeloma that has come back or stopped responding to their first treatment. It will enroll about 80 adults and measure how…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC